Literature DB >> 25762474

IBD and the gut microbiota--from bench to personalized medicine.

Emanuelle Bellaguarda1, Eugene B Chang.   

Abstract

Inflammatory bowel diseases (IBD) are chronic relapsing inflammatory disorders involving the gastrointestinal (GI) tract, which arise from the confluence of genetic, immunological, microbial, and environmental factors. Clinical, genetic, and experimental data support the role of gut microbiota in contributing to the etiopathogenesis of these diseases. In IBD, the development of gut dysbiosis and imbalances in host-microbe relationships contribute to the extent, severity, and chronicity of intestinal inflammation. With continued advances in knowledge, technology, bioinformatics tools, and capabilities to define disease subsets, we will be able to lower risk and improve clinical outcomes in IBD through individualized interventions that restore host-microbial balance. This article provides a critical review of the field, based on the latest clinical and experimental information.

Entities:  

Mesh:

Year:  2015        PMID: 25762474     DOI: 10.1007/s11894-015-0439-z

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  94 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 2.  Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases.

Authors:  Charles N Bernstein; Fergus Shanahan
Journal:  Gut       Date:  2008-05-30       Impact factor: 23.059

3.  Fecal matters.

Authors:  Roxanne Palmer
Journal:  Nat Med       Date:  2011-02       Impact factor: 53.440

4.  Treatment of ulcerative colitis by implantation of normal colonic flora.

Authors:  J D Bennet; M Brinkman
Journal:  Lancet       Date:  1989-01-21       Impact factor: 79.321

5.  Patient perceptions of fecal microbiota transplantation for ulcerative colitis.

Authors:  Stacy A Kahn; Ashley Vachon; Dylan Rodriquez; Sarah R Goeppinger; Bonnie Surma; Julia Marks; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2013-06       Impact factor: 5.325

6.  Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials.

Authors:  Jun Shen; Zhi-Xiang Zuo; Ai-Ping Mao
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

7.  Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease.

Authors:  Wei Wang; Liping Chen; Rui Zhou; Xiaobing Wang; Lu Song; Sha Huang; Ge Wang; Bing Xia
Journal:  J Clin Microbiol       Date:  2013-11-13       Impact factor: 5.948

8.  Linking long-term dietary patterns with gut microbial enterotypes.

Authors:  Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis
Journal:  Science       Date:  2011-09-01       Impact factor: 47.728

Review 9.  Current concepts on the immunopathogenesis of inflammatory bowel disease.

Authors:  Puja Vora; David Quan Shih; Dermot Patrick McGovern; Stephan Raoul Targan
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

10.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.

Authors:  Xochitl C Morgan; Timothy L Tickle; Harry Sokol; Dirk Gevers; Kathryn L Devaney; Doyle V Ward; Joshua A Reyes; Samir A Shah; Neal LeLeiko; Scott B Snapper; Athos Bousvaros; Joshua Korzenik; Bruce E Sands; Ramnik J Xavier; Curtis Huttenhower
Journal:  Genome Biol       Date:  2012-04-16       Impact factor: 13.583

View more
  17 in total

Review 1.  Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.

Authors:  Ersilia M DeFilippis; Randy Longman; Michael Harbus; Kyle Dannenberg; Ellen J Scherl
Journal:  Curr Gastroenterol Rep       Date:  2016-03

Review 2.  The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions.

Authors:  Stephen M Vindigni; Timothy L Zisman; David L Suskind; Christopher J Damman
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

Review 3.  The zebrafish as a model for gastrointestinal tract-microbe interactions.

Authors:  Erika M Flores; Anh T Nguyen; Max A Odem; George T Eisenhoffer; Anne Marie Krachler
Journal:  Cell Microbiol       Date:  2020-01-07       Impact factor: 3.715

4.  Comparative Effect of the I3.1 Probiotic Formula in Two Animal Models of Colitis.

Authors:  Violeta Lorén; Josep Manyé; Mari C Fuentes; Eduard Cabré; Isabel Ojanguren; Jordi Espadaler
Journal:  Probiotics Antimicrob Proteins       Date:  2017-03       Impact factor: 4.609

5.  A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition.

Authors:  Dalin Li; Jean-Paul Achkar; Talin Haritunians; Jonathan P Jacobs; Ken Y Hui; Mauro D'Amato; Stephan Brand; Graham Radford-Smith; Jonas Halfvarson; Jan-Hendrik Niess; Subra Kugathasan; Carsten Büning; L Philip Schumm; Lambertus Klei; Ashwin Ananthakrishnan; Guy Aumais; Leonard Baidoo; Marla Dubinsky; Claudio Fiocchi; Jürgen Glas; Raquel Milgrom; Deborah D Proctor; Miguel Regueiro; Lisa A Simms; Joanne M Stempak; Stephan R Targan; Leif Törkvist; Yashoda Sharma; Bernie Devlin; James Borneman; Hakon Hakonarson; Ramnik J Xavier; Mark Daly; Steven R Brant; John D Rioux; Mark S Silverberg; Judy H Cho; Jonathan Braun; Dermot P B McGovern; Richard H Duerr
Journal:  Gastroenterology       Date:  2016-08-01       Impact factor: 22.682

6.  GelNB molecular coating as a biophysical barrier to isolate intestinal irritating metabolites and regulate intestinal microbial homeostasis in the treatment of inflammatory bowel disease.

Authors:  Qijiang Mao; Haoqi Pan; Yiyin Zhang; Yi Zhang; Qiuwen Zhu; Yi Hong; Zhengze Huang; Yang Li; Xu Feng; Yifeng Fang; WenChao Chen; Pengfei Chen; Bo Shen; Hongwei Ouyang; Yuelong Liang
Journal:  Bioact Mater       Date:  2022-04-21

7.  Long noncoding RNA expression profiles in gut tissues constitute molecular signatures that reflect the types of microbes.

Authors:  Lunxi Liang; Luoyan Ai; Jin Qian; Jing-Yuan Fang; Jie Xu
Journal:  Sci Rep       Date:  2015-06-30       Impact factor: 4.379

8.  Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders.

Authors:  Hani Sbahi; Jack A Di Palma
Journal:  BMJ Open Gastroenterol       Date:  2016-05-09

Review 9.  The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood.

Authors:  John Slattery; Derrick F MacFabe; Richard E Frye
Journal:  Clin Med Insights Pediatr       Date:  2016-10-09

Review 10.  Flavonoids in Inflammatory Bowel Disease: A Review.

Authors:  Teresa Vezza; Alba Rodríguez-Nogales; Francesca Algieri; Maria Pilar Utrilla; Maria Elena Rodriguez-Cabezas; Julio Galvez
Journal:  Nutrients       Date:  2016-04-09       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.